NDATOPICALGEL
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DIFFERIN (adapalene) by Galderma is 12. First approved in 1996.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIFFERIN (adapalene) is a third-generation retinoid topical gel approved for acne treatment that binds to specific retinoic acid nuclear receptors to modulate cellular differentiation, keratinization, and inflammatory processes. It is applied once daily to affected skin areas and demonstrates minimal systemic absorption with a mean half-life of 17.2 hours. The mechanism of action for acne efficacy remains incompletely characterized despite established biochemical activity.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling team consolidation and transition focus from growth to retention strategies.
Mechanism of Action
12.1 Mechanism of Action Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory…
Worked on DIFFERIN at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.